JP2011515478A - 結腸直腸がんを処置または予防するための方法 - Google Patents

結腸直腸がんを処置または予防するための方法 Download PDF

Info

Publication number
JP2011515478A
JP2011515478A JP2011501946A JP2011501946A JP2011515478A JP 2011515478 A JP2011515478 A JP 2011515478A JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011515478 A JP2011515478 A JP 2011515478A
Authority
JP
Japan
Prior art keywords
antibody
inhibitor
cdr
ser
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011501946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515478A5 (OSRAM
Inventor
ヤオリン ワン，
ヤン ワン，
ミン リュー，
ウォルター ロバート ビショップ，
シンシア シーデル−ドゥーガン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2011515478A publication Critical patent/JP2011515478A/ja
Publication of JP2011515478A5 publication Critical patent/JP2011515478A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011501946A 2008-03-25 2009-03-23 結腸直腸がんを処置または予防するための方法 Pending JP2011515478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3919708P 2008-03-25 2008-03-25
US61/039,197 2008-03-25
PCT/US2009/037953 WO2009142810A2 (en) 2008-03-25 2009-03-23 Methods for treating or preventing colorectal cancer

Publications (2)

Publication Number Publication Date
JP2011515478A true JP2011515478A (ja) 2011-05-19
JP2011515478A5 JP2011515478A5 (OSRAM) 2013-03-14

Family

ID=41340744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501946A Pending JP2011515478A (ja) 2008-03-25 2009-03-23 結腸直腸がんを処置または予防するための方法

Country Status (8)

Country Link
US (1) US20110104256A1 (OSRAM)
EP (1) EP2259797A2 (OSRAM)
JP (1) JP2011515478A (OSRAM)
CA (1) CA2718918A1 (OSRAM)
CL (1) CL2009000721A1 (OSRAM)
MX (1) MX2010010480A (OSRAM)
TW (1) TW200944233A (OSRAM)
WO (1) WO2009142810A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016003224A (ja) * 2014-06-19 2016-01-12 大原薬品工業株式会社 ホリナートカルシウム含有錠
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
WO2010093789A2 (en) 2009-02-12 2010-08-19 Arqule, Inc. Combinational compositions and methods for treatment of cancer
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8580764B2 (en) * 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
TW201221126A (en) 2010-09-01 2012-06-01 Arqule Inc Methods for treatment of non-small cell lung cancer
NL2010276C2 (en) * 2013-02-08 2014-08-11 Stichting Vu Vumc Biomarkers.
EP2841947B1 (en) * 2012-04-26 2019-10-09 Stichting VUmc Biomarkers
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2016054055A1 (en) * 2014-09-29 2016-04-07 Board Of Regent, The University Of Texas System Prediction of response to parp inhibitors and combinational therapy targeting c-met and parp1
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
PL3337478T5 (pl) 2015-08-21 2026-05-04 Ipsen Biopharm Ltd. Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami
WO2017136671A1 (en) * 2016-02-04 2017-08-10 Chattterjee Bandana Combination therapy for castration-resistant prostate cancer
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
WO2020100969A1 (ja) * 2018-11-14 2020-05-22 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物
MX2024000965A (es) * 2021-07-27 2024-02-09 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033006A2 (en) * 2004-09-22 2006-03-30 Pfizer Inc., Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2007075554A2 (en) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
JP2007277242A (ja) * 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8535501A1 (es) * 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
DK1656391T3 (da) * 2003-08-13 2011-01-03 Pfizer Prod Inc Modificerede humane IGF-1R antistoffer
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
US20100143340A1 (en) * 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033006A2 (en) * 2004-09-22 2006-03-30 Pfizer Inc., Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2007075554A2 (en) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
JP2007277242A (ja) * 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016003224A (ja) * 2014-06-19 2016-01-12 大原薬品工業株式会社 ホリナートカルシウム含有錠
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠

Also Published As

Publication number Publication date
TW200944233A (en) 2009-11-01
WO2009142810A2 (en) 2009-11-26
CA2718918A1 (en) 2009-11-26
MX2010010480A (es) 2010-10-15
WO2009142810A3 (en) 2010-07-15
EP2259797A2 (en) 2010-12-15
CL2009000721A1 (es) 2010-05-14
US20110104256A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
US20110104256A1 (en) Methods for treating or preventing colorectal cancer
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
US20110014117A1 (en) Anti-igf1r
US8216571B2 (en) Fully human anti-VEGF antibodies and methods of using
JP6695295B2 (ja) 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用
US8933202B2 (en) AXL antibodies
TWI476206B (zh) 對肝細胞生長因子具專一性之結合劑
EP2104501B1 (en) Methods of cancer treatment with igf1r inhibitors
CN103957935B (zh) 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
EA023555B1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
JP2009505676A (ja) Ｔｒａｉｌ受容体２ポリペプチダーゼ及び抗体
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2005200421A (ja) 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
EP2121018A2 (en) Treating cancer with anti-igf1r antibody 19d12=sch 717454
WO2011057064A1 (en) Igf1r inhibitor based treatment of prostate cancer
JP4875064B2 (ja) 癌を処置または予防するための方法および組成物
CN120865400B (zh) Fgf18中和抗体及其制备方法和应用、核酸分子、载体、细胞、药物和联合用药组合物
EP4393515A1 (en) Anti-cldn-18.2 antibody-drug conjugate and use thereof
US20150152193A1 (en) Axl antibodies
AU2016203429B2 (en) Binding Molecules to the Human OX40 Receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131016